Prentice C R
Department of Clinical Medicine, General Infirmary and University of Leeds, UK.
Haemostasis. 1998;28 Suppl 3:109-12. doi: 10.1159/000022387.
Chemoprophylaxis with subcutaneous low-molecular-weight heparin has been shown to reduce deep vein thrombosis detected by surrogate endpoints such as fibrinogen scanning and venography. However, there have been few trials which have assessed clinical endpoints attributed to fatal and non-fatal pulmonary embolism following surgery. As these clinical endpoints are rare, large-scale trials using vascular mortality, vascular morbidity and the incidence of haemorrhage as clinical endpoints need to be performed to assess the efficacy of chemical thromboprophylaxis. The benefit of using clinical endpoints against the risk of haemorrhage should also be evaluated.
皮下注射低分子量肝素进行化学预防已被证明可减少通过纤维蛋白原扫描和静脉造影等替代终点检测到的深静脉血栓形成。然而，很少有试验评估手术后归因于致命和非致命性肺栓塞的临床终点。由于这些临床终点很少见，因此需要进行以血管死亡率、血管发病率和出血发生率作为临床终点的大规模试验，以评估化学血栓预防的疗效。还应评估使用临床终点相对于出血风险的益处。
